The hormone adrenomedullin disrupts insulin signaling in blood vessel cells, contributing to systemic insulin resistance in obesity-associated type 2 diabetes, according to a new study.

Now, Boston Children's Division of Endocrinology researchers have discovered another purpose for BRD7: It seems to be involved in an alternative insulin signaling pathway, the existence of which ...

Researchers from the German Diabetes Center (DDZ) and the Heinrich Heine University Düsseldorf (HHU) have studied the ...

One possibility is that in an attempt to overcome the inhibition within the metabolic insulin-signaling pathway, hyperinsulinemia may continue to stimulate the mitogenic insulin-signaling pathway ...

Studies have shown that during the development of insulin resistance, many steps in the metabolic pathway activated by insulin are altered. However, much less attention has so far been paid to ...

disrupts the effect of insulin on the endothelium of blood vessels, leading to insulin resistance linked to obesity and type 2 diabetes. The clue to this discovery lies in a molecular pathway that ...

In addition, there is evidence that in type 2 diabetes, the activation of these same pathways by elevations in glucose and free fatty acid (FFA) levels leads to both insulin resistance and ...

The Europe-wide approval is the first ever insulin treatment licensed through the European Medicines Agency's biosimilar pathway, and the fourth diabetes product approved in the EU from the Lilly ...